Endo Pharmaceuticals, a specialty pharmaceutical company, completed the acquisition of BioSpecifics, a commercial-stage biopharmaceutical company, for $658m. "BioSpecifics Technologies pioneered the development of collagenase-based therapies, which has resulted in a robust injectable collagenase portfolio, consisting of XIAFLEX to treat the vast number of diseases and medical conditions caused by the excess accumulation of collagen and Qwo for the treatment of cellulite," Joseph Truitt, BioSpecifics Chief Executive Officer.